作者
Egon Demetz,Andrea Schroll,Kristina Auer,Christiane Heim,Josef R. Patsch,Kathrin Eller,Markus Theurl,Igor Theurl,Milan Theurl,Markus Seifert,Daniela Lener,Ursula Stanzl,David Haschka,Malte Aßhoff,Stefanie Dichtl,Manfred Nairz,E. Huber,Martin Stadlinger,Alexander R. Moschen,Xiaorong Li,Petra Pallweber,Hubert Scharnagl,Tatjana Stojaković,Winfried März,Marcus E. Kleber,K. Garlaschelli,Patrizia Uboldi,Alberico L. Catapano,Frans Stellaard,Mats Rudling,Keiji Kuba,Yumiko Imai,Makoto Arita,John D. Schuetz,Peter P. Pramstaller,Uwe J.F. Tietge,Michael Trauner,Giuseppe Danilo Norata,Thierry Claudel,Andrew A. Hicks,Günter Weiß,Ivan Tancevski
摘要
Cholesterol metabolism is closely interrelated with cardiovascular disease in humans. Dietary supplementation with omega-6 polyunsaturated fatty acids including arachidonic acid (AA) was shown to favorably affect plasma LDL-C and HDL-C. However, the underlying mechanisms are poorly understood. By combining data from a GWAS screening in >100,000 individuals of European ancestry, mediator lipidomics, and functional validation studies in mice, we identify the AA metabolome as an important regulator of cholesterol homeostasis. Pharmacological modulation of AA metabolism by aspirin induced hepatic generation of leukotrienes (LTs) and lipoxins (LXs), thereby increasing hepatic expression of the bile salt export pump Abcb11. Induction of Abcb11 translated in enhanced reverse cholesterol transport, one key function of HDL. Further characterization of the bioactive AA-derivatives identified LX mimetics to lower plasma LDL-C. Our results define the AA metabolomeasconserved regulator of cholesterol metabolism, and identify AA derivatives as promising therapeutics to treat cardiovascular disease in humans.